Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07496918 · ClinicalTrials.gov registry record · Phase 2
Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)
A Phase 2 study, sponsored by Massachusetts Institute of Technology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT07496918 is a Phase 2 study that is actively recruiting participants, run by Massachusetts Institute of Technology. The registered enrollment target is 150 participants.
The verdict
NCT07496918, a Phase 2 study, is actively recruiting participants, sponsored by Massachusetts Institute of Technology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
Despite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that is effective in slowing cognitive impairment is not only revolutionary but also possibly cost- effective. In this study, participants will come to MIT for a 1-day visit and the investigators will evaluate the effects of GENUS in cognitively normal, healthy adults. Investigators will use Electroencephalogram (EEG), Magnetoencephalography (MEG), magnetic resonance imaging (MRI), neuropsychological testing, and blood sampling in subsets of participants to evaluate for biological effects and safety of GENUS stimulation.
Interventions
- DEVICE GENUS
- DEVICE Tactile GENUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07496918
The ClinicalTrials.gov registry entry for NCT07496918 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts Institute of Technology, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GENUS is the first listed.
NCT07496918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07496918 about?
NCT07496918 is a clinical study titled "Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)". Despite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that is effective in slo...
What is the current status of trial NCT07496918?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2018-02-20. Estimated completion is 2027-01-30.
What interventions are being tested in trial NCT07496918?
The interventions under investigation include: GENUS (DEVICE), Tactile GENUS (DEVICE).
Who is sponsoring clinical trial NCT07496918?
This trial is sponsored by Massachusetts Institute of Technology, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.